Cediranib, olaparib combo not superior in ovarian cancer outside of germline mutations
Click Here to Manage Email Alerts
Though the combination of cediranib and olaparib did not beat out platinum-based chemotherapy, it was more effective in patients with germline BRCA mutations, according to Ursula A. Matulonis, MD, of Dana Farber Cancer Institute.
The study presented by Joyce Liu, MD, also of Dana Farber, during the ASCO2020 Virtual Scientific Program compared the combination therapy to olaparib (Lynparza; AstraZeneca, Merck) alone and platinum-based chemotherapy in a randomized phase 3 trial.
“During the course of this study, the standard of care changed,” Matulonis said, referring to PARP inhibitors becoming the standard of care.
“Cediranib (AstraZeneca)-olaparib unfortunately did not meet the primary endpoint of improved progression free survival compared to platinum-based chemotherapy but actually did have comparable activity,” Matulonis said. “It was found that cediranib and olaparib as well as olaparib alone performed better than chemotherapy in patients with an underlying germline BRCA mutation. In the patients with BRCA wild type [tumors], chemotherapy performed the best with cediranib-olaparib comparable. But in BRCA wild type, olaparib alone was inferior.”
Collapse
Liu JF, et al. Abstract 6003. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Read more about
Click Here to Manage Email Alerts